• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical outcomes at 1 year in early Psoriasis Area and Severity Index responders compared with non-responders: Subgroup analysis of UNCOVER-3 trial.

作者信息

Rosmarin D, Smith S, Shrom D, Burge R, See K, McKean-Matthews M, Ridenour T, Lin C-Y, Gorelick J

机构信息

Tufts Medical Center Boston Massachusetts USA.

California Dermatology and Clinical Research Institute Encinitas California USA.

出版信息

Skin Health Dis. 2021 May 11;1(3):e43. doi: 10.1002/ski2.43. eCollection 2021 Sep.

DOI:10.1002/ski2.43
PMID:35663140
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9060090/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e89e/9060090/81916671904e/SKI2-1-e43-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e89e/9060090/81916671904e/SKI2-1-e43-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e89e/9060090/81916671904e/SKI2-1-e43-g002.jpg

相似文献

1
Clinical outcomes at 1 year in early Psoriasis Area and Severity Index responders compared with non-responders: Subgroup analysis of UNCOVER-3 trial.早期银屑病面积和严重程度指数应答者与无应答者1年时的临床结局：UNCOVER-3试验的亚组分析
Skin Health Dis. 2021 May 11;1(3):e43. doi: 10.1002/ski2.43. eCollection 2021 Sep.
2
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).在依那西普无反应者中转换为司库奇尤单抗的疗效和安全性：来自两项中重度斑块状银屑病III期随机临床试验（UNCOVER-2和-3）的亚组分析
Am J Clin Dermatol. 2017 Apr;18(2):273-280. doi: 10.1007/s40257-016-0246-9.
3
Predictors of Psoriasis Area and Severity Index 100 response in Korean patients with moderate-to-severe plaque psoriasis receiving biologics.预测生物制剂治疗中重度斑块状银屑病韩国患者达到银屑病面积和严重程度指数 100 缓解的因素。
Eur J Dermatol. 2023 Oct 1;33(5):518-523. doi: 10.1684/ejd.2023.4555.
4
Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).使用司库奇尤单抗治疗中度至重度头皮受累银屑病的持续缓解：三项3期试验（UNCOVER-1、UNCOVER-2、UNCOVER-3）的结果
J Dermatolog Treat. 2017 Jun;28(4):282-287. doi: 10.1080/09546634.2016.1249820. Epub 2016 Nov 13.
5
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials.中度至重度银屑病患者使用司库奇尤单抗5年的疗效和安全性：UNCOVER-1和UNCOVER-2 3期随机对照试验的长期结果
Dermatol Ther (Heidelb). 2020 Jun;10(3):431-447. doi: 10.1007/s13555-020-00367-x. Epub 2020 Mar 21.
6
Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes.用于比较依奇珠单抗与依那西普和安慰剂在中重度斑块状银屑病患者中的疗效的绝对和相对银屑病面积和严重程度指数（PASI）：UNCOVER-2 和 UNCOVER-3 结局的综合分析。
Acta Derm Venereol. 2019 Oct 1;99(11):971-977. doi: 10.2340/00015555-3245.
7
Cost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis.与司库奇尤单抗和依那西普治疗中重度银屑病相关的每增加一名缓解者的成本。
J Drugs Dermatol. 2017 Dec 1;16(12):1246-1252.
8
Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real-life clinical setting in Italy: the TRANSITION study.意大利真实临床环境中中重度斑块型银屑病患者应用环孢素 A 的疗效：TRANSITION 研究。
J Dermatolog Treat. 2022 Feb;33(1):401-407. doi: 10.1080/09546634.2020.1757017. Epub 2020 Apr 30.
9
Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study.接受二甲基富马酸（DMF）治疗的中重度斑块型银屑病成人的生活质量结局：BRIDGE 研究的事后分析。
J Eur Acad Dermatol Venereol. 2020 Jan;34(1):119-126. doi: 10.1111/jdv.15922. Epub 2019 Oct 17.
10
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.依奇珠单抗治疗中重度斑块状银屑病的 3 期临床试验。
N Engl J Med. 2016 Jul 28;375(4):345-56. doi: 10.1056/NEJMoa1512711. Epub 2016 Jun 8.

引用本文的文献

1
Predicting the Time to Relapse Following Withdrawal from Different Biologics in Patients with Psoriasis who Responded to Therapy: A 12-Year Multicenter Cohort Study.预测对治疗有反应的银屑病患者在停用不同生物制剂后的复发时间：一项为期 12 年的多中心队列研究。
Am J Clin Dermatol. 2024 Nov;25(6):997-1008. doi: 10.1007/s40257-024-00887-8. Epub 2024 Sep 16.

本文引用的文献

1
Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Analysis from a Long-term Clinical Study.预测中重度斑块状银屑病患者长期皮肤病生活质量指数反应的早期治疗靶点：一项长期临床研究的分析
J Clin Aesthet Dermatol. 2020 Oct;13(10):18-22. Epub 2020 Oct 1.
2
Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab.接受司库奇尤单抗或阿达木单抗治疗的银屑病患者的真实世界治疗模式比较。
Patient Prefer Adherence. 2020 Mar 9;14:517-527. doi: 10.2147/PPA.S233993. eCollection 2020.
3
Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.
比较依奇珠单抗或司库奇尤单抗治疗银屑病患者的真实世界治疗模式。
J Am Acad Dermatol. 2020 Apr;82(4):927-935. doi: 10.1016/j.jaad.2019.11.015. Epub 2019 Nov 8.
4
Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies.司库奇尤单抗治疗对中度至重度斑块状银屑病患者瘙痒及银屑病面积和严重程度指数的影响：两项III期随机研究的综合分析
Dermatol Ther (Heidelb). 2018 Dec;8(4):621-637. doi: 10.1007/s13555-018-0267-9. Epub 2018 Nov 21.
5
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.司库奇尤单抗治疗中重度斑块状银屑病的3期试验
N Engl J Med. 2016 Nov 24;375(21):2102. doi: 10.1056/NEJMc1610828.
6
Patient-relevant treatment goals in psoriasis.银屑病中与患者相关的治疗目标。
Arch Dermatol Res. 2016 Mar;308(2):69-78. doi: 10.1007/s00403-015-1613-8. Epub 2015 Dec 19.
7
Conversations on psoriasis--what patients want and what physicians can provide: a qualitative look at patient and physician expectations.银屑病医患对话——患者需求与医生所能提供：对患者与医生期望的定性分析。
J Dermatolog Treat. 2010 Jan;21(1):6-12. doi: 10.3109/09546630903085328.